Breaking News, Trials & Filings

Swissmedic Begins Rolling Review of Moderna’s mRNA COVID-19 Vax

Moderna completed enrollment of its Phase 3 COVE study of mRNA-1273 on October 22.

By: Contract Pharma

Contract Pharma Staff

Moderna, Inc. announced that Swissmedic has started a rolling review of mRNA-1273, the Company’s vaccine candidate against COVID-19. This follows positive results from a preclinical viral challenge study of mRNA-1273 and the positive interim analysis of the Phase 1 study of mRNA-1273 in adults (ages 18-55 years) and older adults (ages 56-70 and 71+). Moderna has initiated the rolling submission of mRNA-1273 data in consideration of a potential authorization for use of the vaccine candidate in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters